What Research Use Only actually means

“For research use only” sounds like fine print until you notice how regulators read it. They treat it as a statement of intended use. If photographs, captions, and guides describe human treatment, a footer disclaimer does not quietly reverse that story. Intended use is about the whole presentation — what the product is offered for — not only the smallest type on the page.

Compounding is a different pathway

503A and 503B compounding is how a pharmacy may prepare a drug that is not a commercially available FDA-approved product, under conditions set out in the FD&C Act. It is a regulated pharmacy pathway, not a research-chemical website becoming a clinic. FDA’s Category 2 list exists for bulk substances nominated for compounding that the Agency has said may present significant safety risks — immunogenicity, impurity, and limited human data among the concerns.

BPC-157 sat in that Category 2 conversation after 2023. In July 2026 the Pharmacy Compounding Advisory Committee put BPC-157, KPV, TB-500, and MOTS-c related bulk substances on the agenda for 503A list discussion. An agenda is a public conversation — useful context, not an approval. A committee discussion sits well short of an NDA. A research vial on a storefront remains a research chemical: distinct from a compounded drug, from Forzinity, and from a prescription.

Intended use is read from the whole product story — photos, captions, and claims — not from the footer alone.

The 2026 vendor shakeout — warning letters, shutdowns, and a proposed SAFE Drugs Act conversation around research chemicals that are biologically identical to approved drugs — is what a market looks like when intended use was treated casually. The steadier response is a narrower claim: this is a chemical for laboratory research, with a lot number you can check.